HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	PF-06873600 Sensitive: C2 – Inclusion Criteria PF-06873600 Sensitive : C2	PF-06873600 Sensitive: C2 – Inclusion Criteria PF-06873600 Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	TQB3616 Sensitive: C2 – Inclusion Criteria TQB3616 Sensitive : C2	TQB3616 Sensitive: C2 – Inclusion Criteria TQB3616 Sensitive : C2
CCNE1 overexpression	Estrogen Receptor Positive Breast Cancer	CCNE1 overexpression	Estrogen Receptor Positive Breast Cancer	RGT-419B Sensitive: D – Preclinical RGT-419B Sensitive : D	RGT-419B Sensitive: D – Preclinical RGT-419B Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	RGT-419B Sensitive: D – Preclinical RGT-419B Sensitive : D	RGT-419B Sensitive: D – Preclinical RGT-419B Sensitive : D
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	TQB3616 Sensitive: D – Preclinical TQB3616 Sensitive : D	TQB3616 Sensitive: D – Preclinical TQB3616 Sensitive : D

CDK2/4/6 inhibitor

Associations(5)